NR3C1 (Glucocorticoid receptor) variants and mutations
NR3C1 (also known as Glucocorticoid receptor) is a human protein-coding gene encoding a glucocorticoid receptor protein. It converts glucocorticoid binding into transcriptional programs that regulate metabolism, stress responses, inflammation, and immune activity. Loss-of-function variants can cause glucocorticoid resistance, while excessive or prolonged signaling underlies many adverse effects of corticosteroid therapy. This analysis covers 1,075 NR3C1 variants and mutations. Of these, 89% have computational variant effect predictions. Disease context includes glucocorticoid resistance, chronic obstructive pulmonary disease, and multiple sclerosis. Example NR3C1 variants include M1?, S3C, and S3F.
Variant analysis overview
- Gene: NR3C1
- Protein: Glucocorticoid receptor
- UniProt accession: P04150
- Organism: Homo sapiens
- Variants analyzed: 1075
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 885 unspecified-consequence records; 5 stop lost; 1 stop retained variant; 15 frameshift variants; 71 synonymous variants; 86 missense variants; 5 stop-gained variants; 1 in-frame insertions; 3 splice-region variants; 1 in-frame deletions; 1 substitution
- Prediction scores: 959 variants have prediction scores (89% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: glucocorticoid resistance, chronic obstructive pulmonary disease, multiple sclerosis, rheumatoid arthritis, asthma, plasma cell myeloma, sarcoidosis, infection, autoimmune thrombocytopenic purpura, osteoarthritis, prostate cancer, ulcerative colitis.
Protein structure and variant hotspots
- Protein features: 1 domains; 17 post-translational modification sites.
- Structural context: 353 variants have structural context.
- PTM context: 17 variants overlap post-translational modification sites.
- Experimental data: 76 protein positions have experimental scores. Source: NR3C1 Zinc finger, nuclear hormone receptor-type domain domainome 1.0.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable NR3C1 variants
Examples include M1?, S3C, S3F, E5*, S6*, T8A, T8S, P9H. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, NCI-TCGA Cosmic COSV5154, cosmic curated COSV51546, Variant assessed as somatic; high impact.
- S3C (p.Ser3Cys), Ensembl rs971891763
- S3F (p.Ser3Phe), cosmic curated COSV10457, MetaLR 0.57, MetaSVM -0.63
- E5* (p.Glu5Ter), NCI-TCGA Cosmic COSV9919, cosmic curated COSV99196, Variant assessed as somatic; high impact.
- S6* (p.Ser6Ter), NCI-TCGA TCGA novel, CADD 36.00, Variant assessed as somatic; high impact.
- T8A (p.Thr8Ala), TOPMed rs1244197690, gnomAD rs1244197690, REVEL 0.16, CADD 16.30
- T8S (p.Thr8Ser), ExAC rs773373601, gnomAD rs773373601, REVEL 0.19, CADD 2.30
- P9H (p.Pro9His), NCI-TCGA Cosmic COSV5153, cosmic curated COSV51539, MetaLR 0.63, MetaSVM -0.30, Variant assessed as somatic; moderate impact.
- P9S (p.Pro9Ser), 1000Genomes rs61759024, ESP rs61759024, ExAC rs61759024, TOPMed rs61759024, REVEL 0.08, CADD 0.09, Uncertain significance, not provided
- G10D (p.Gly10Asp), TOPMed rs1840132234, MetaLR 0.39, MetaSVM -0.79
- G10R (p.Gly10Arg), TOPMed rs1182025204, gnomAD rs1182025204, REVEL 0.18, CADD 4.09
- G10S (p.Gly10Ser), rs941700497, []
- R11G (p.Arg11Gly), NCI-TCGA TCGA novel, REVEL 0.15, CADD 15.90, Variant assessed as somatic; moderate impact.
- R11I (p.Arg11Ile), cosmic curated COSV51540, REVEL 0.12, CADD 16.00
- E12K (p.Glu12Lys), Ensembl rs1840131436
- E13G (p.Glu13Gly), cosmic curated COSV10956
- E13K (p.Glu13Lys), TOPMed rs1840130610
- E13Q (p.Glu13Gln), cosmic curated COSV51539, MetaLR 0.72, MetaSVM -0.29
- E13V (p.Glu13Val), TOPMed rs1013873148, gnomAD rs1013873148, REVEL 0.27, CADD 23.00, Uncertain significance, Inborn genetic diseases
- N14D (p.Asn14Asp), gnomAD rs1413592008, REVEL 0.10, CADD 10.20
- N14K (p.Asn14Lys), ExAC rs768900943, gnomAD rs768900943, REVEL 0.13, CADD 7.48
- P15L (p.Pro15Leu), cosmic curated COSV51547, gnomAD rs1426382191, REVEL 0.13, CADD 14.20
- S16G (p.Ser16Gly), Ensembl rs2151942144
- S16R (p.Ser16Arg), TOPMed rs991303685, gnomAD rs991303685
- S16S (p.Ser16Ser), rs991303685, []
- A20T (p.Ala20Thr), cosmic curated COSV10608
- Q21* (p.Gln21Ter), rs895053872, Ensembl rs895053872, Variant assessed as somatic; high impact.
- Q21R (p.Gln21Arg), ExAC rs746718874, TOPMed rs746718874, gnomAD rs746718874, REVEL 0.13, CADD 1.03, Likely benign, Inborn genetic diseases
- E22* (p.Glu22Ter), NCI-TCGA Cosmic COSV9919, cosmic curated COSV99196, Variant assessed as somatic; high impact.
- E22D (p.Glu22Asp), 1000Genomes rs6189, ESP rs6189, ExAC rs6189, TOPMed rs6189, REVEL 0.08, CADD 16.10, Benign
- R23K (p.Arg23Lys), rs6190, ClinGen CA3487144, cosmic curated COSV99039, ClinVar RCV000317840, REVEL 0.14, CADD 21.10, Uncertain significance, not provided; Glucocorticoid resistance
- R23S (p.Arg23Ser), cosmic curated COSV99196
- R23T (p.Arg23Thr), 1000Genomes rs6190, ESP rs6190, ExAC rs6190, TOPMed rs6190, REVEL 0.11, CADD 23.00, Benign
- D25G (p.Asp25Gly), rs1047437679, Ensembl rs1047437679, REVEL 0.08, CADD 22.40, Variant assessed as somatic; moderate impact.
- D25N (p.Asp25Asn), Ensembl rs72481829, MetaLR 0.20, MetaSVM -0.99
- M27T (p.Met27Thr), ExAC rs778329686, TOPMed rs778329686, gnomAD rs778329686, REVEL 0.12, CADD 23.50
- M27V (p.Met27Val), TOPMed rs1840122406, MetaLR 0.05, MetaSVM -1.08
- D28N (p.Asp28Asn), Ensembl rs866665037, REVEL 0.06, CADD 23.80
- F29L (p.Phe29Leu), rs148102613, UniProt VAR 015628, ESP rs148102613, ExAC rs148102613, REVEL 0.01, CADD 19.00, Uncertain significance, Glucocorticoid resistance
- Y30C (p.Tyr30Cys), ExAC rs755833578, TOPMed rs755833578, gnomAD rs755833578, REVEL 0.15, CADD 21.80, Uncertain significance, not provided; Glucocorticoid resistance
- Y30H (p.Tyr30His), rs143711342, ClinGen CA3487139, ClinVar RCV000937948, ClinVar RCV001152117, REVEL 0.06, CADD 21.00, Conflicting interpretations, not provided; Glucocorticoid resistance
- Y30N (p.Tyr30Asn), ESP rs143711342, ExAC rs143711342, TOPMed rs143711342, gnomAD rs143711342, REVEL 0.08, CADD 21.60, Likely benign
- K31R (p.Lys31Arg), TOPMed rs943559773, gnomAD rs943559773, REVEL 0.07, CADD 22.70
- T32A (p.Thr32Ala), TOPMed rs1295406423
- T32N (p.Thr32Asn), TOPMed rs1316606842
- T32S (p.Thr32Ser), TOPMed rs1295406423, MetaLR 0.06, MetaSVM -1.06
- L33I (p.Leu33Ile), cosmic curated COSV10956
- L33V (p.Leu33Val), ExAC rs751852777, gnomAD rs751852777, REVEL 0.14, CADD 16.90
- R34G (p.Arg34Gly), gnomAD rs1285746796, REVEL 0.24, CADD 28.70
- G35E (p.Gly35Glu), ESP rs374312820, ExAC rs374312820, TOPMed rs374312820, gnomAD rs374312820, REVEL 0.27, CADD 24.30
- G36E (p.Gly36Glu), ExAC rs750532455, TOPMed rs750532455, gnomAD rs750532455, REVEL 0.48, CADD 26.50
- G36V (p.Gly36Val), rs750532455, NCI-TCGA Cosmic COSV5154, cosmic curated COSV51544, ExAC rs750532455, REVEL 0.55, CADD 26.60, Variant assessed as somatic; moderate impact.
- A37D (p.Ala37Asp), ExAC rs765396873, gnomAD rs765396873, REVEL 0.20, CADD 25.30
- A37S (p.Ala37Ser), cosmic curated COSV10437, MetaLR 0.10, MetaSVM -0.98
- T38A (p.Thr38Ala), gnomAD rs1448288573, REVEL 0.04, CADD 17.80
- V39A (p.Val39Ala), ExAC rs762480353, gnomAD rs762480353, REVEL 0.03, CADD 19.70, Uncertain significance, Glucocorticoid resistance
- K40Q (p.Lys40Gln), TOPMed rs967705315, REVEL 0.07, CADD 22.60
- K40R (p.Lys40Arg), TOPMed rs1840113827, MetaLR 0.05, MetaSVM -1.12
- V41F (p.Val41Phe), gnomAD rs1330057814, REVEL 0.12, CADD 22.50
- S42F (p.Ser42Phe), gnomAD rs1840112153, REVEL 0.07, CADD 22.00, Uncertain significance, not provided
- S42Y (p.Ser42Tyr), NCI-TCGA Cosmic COSV5154, cosmic curated COSV51544, MetaLR 0.10, MetaSVM -1.05, Variant assessed as somatic; moderate impact.
- A43P (p.Ala43Pro), TOPMed rs1389278063, gnomAD rs1389278063, REVEL 0.14, CADD 20.10, Uncertain significance, Glucocorticoid resistance
- A43T (p.Ala43Thr), TOPMed rs1389278063, gnomAD rs1389278063, REVEL 0.04, CADD 20.90, Uncertain significance
- A43V (p.Ala43Val), TOPMed rs1165357659, gnomAD rs1165357659, REVEL 0.01, CADD 14.80
- S44P (p.Ser44Pro), ESP rs148967394, TOPMed rs148967394, gnomAD rs148967394, REVEL 0.08, CADD 22.50
- P46L (p.Pro46Leu), TOPMed rs1021595766, REVEL 0.10, CADD 24.10, Uncertain significance, Glucocorticoid resistance
- P46S (p.Pro46Ser), TOPMed rs1421646652, REVEL 0.04, CADD 8.30
- A49S (p.Ala49Ser), TOPMed rs1840107606, gnomAD rs1840107606, MetaLR 0.07, MetaSVM -1.11
- A49T (p.Ala49Thr), TOPMed rs1840107606, gnomAD rs1840107606, REVEL 0.06, CADD 22.60
- A49V (p.Ala49Val), cosmic curated COSV51542, 1000Genomes rs552377230, ExAC rs552377230, gnomAD rs552377230, REVEL 0.07, CADD 22.10, Uncertain significance, Inborn genetic diseases
- V50G (p.Val50Gly), ExAC rs79138720, gnomAD rs79138720, MetaLR 0.04, MetaSVM -1.09
- A51T (p.Ala51Thr), rs1292025233, NCI-TCGA Cosmic COSV5154, cosmic curated COSV51542, gnomAD rs1292025233, REVEL 0.07, CADD 15.40, Uncertain significance, Inborn genetic diseases
- A51V (p.Ala51Val), cosmic curated COSV10507, MetaLR 0.07, MetaSVM -1.10
- Q53E (p.Gln53Glu), NCI-TCGA Cosmic COSV5154, cosmic curated COSV51547, Variant assessed as somatic; moderate impact.
- Q53L (p.Gln53Leu), 1000Genomes rs1018341081, TOPMed rs1018341081, gnomAD rs1018341081, REVEL 0.07, CADD 21.30, Uncertain significance
- Q53P (p.Gln53Pro), 1000Genomes rs1018341081, TOPMed rs1018341081, gnomAD rs1018341081, REVEL 0.08, CADD 16.70, Uncertain significance, Glucocorticoid resistance
- Q53R (p.Gln53Arg), 1000Genomes rs1018341081, TOPMed rs1018341081, gnomAD rs1018341081, REVEL 0.11, CADD 20.60, Uncertain significance
- S54* (p.Ser54Ter), cosmic curated COSV51543, CADD 37.00
- S56F (p.Ser56Phe), TOPMed rs1840103303, REVEL 0.21, CADD 26.00
- S56P (p.Ser56Pro), ExAC rs770422985, gnomAD rs770422985, REVEL 0.09, CADD 19.90
- K57E (p.Lys57Glu), ExAC rs749288379, TOPMed rs749288379, gnomAD rs749288379, REVEL 0.10, CADD 22.80
- K57T (p.Lys57Thr), TOPMed rs1286609634, gnomAD rs1286609634, REVEL 0.15, CADD 22.60
- Q58H (p.Gln58His), ExAC rs752462910, gnomAD rs752462910, cosmic curated COSV10956, REVEL 0.23, CADD 23.40
- R59* (p.Arg59Ter), rs781064223, ExAC rs781064223, TOPMed rs781064223, gnomAD rs781064223, CADD 37.00, Variant assessed as somatic; high impact.
- R59L (p.Arg59Leu), cosmic curated COSV51543, MetaLR 0.07, MetaSVM -1.03
- R59P (p.Arg59Pro), TOPMed rs1008340994, gnomAD rs1008340994, REVEL 0.10, CADD 14.00, Uncertain significance, not provided
- R59Q (p.Arg59Gln), rs1008340994, NCI-TCGA Cosmic COSV5154, cosmic curated COSV51542, REVEL 0.03, CADD 7.29, Variant assessed as somatic; moderate impact.
- R60K (p.Arg60Lys), TOPMed rs1329822283, gnomAD rs1329822283, REVEL 0.10, CADD 18.70, Uncertain significance, Inborn genetic diseases
- R60T (p.Arg60Thr), NCI-TCGA Cosmic COSV9919, cosmic curated COSV99196, MetaLR 0.06, MetaSVM -1.04, Variant assessed as somatic; moderate impact.
- L61P (p.Leu61Pro), cosmic curated COSV99197
- L62F (p.Leu62Phe), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- L62V (p.Leu62Val), TOPMed rs1217840964
- D64E (p.Asp64Glu), rs924576585, ClinGen CA129264896, ClinVar RCV003738722, ClinVar RCV005037020, REVEL 0.37, CADD 23.70, Uncertain significance, Inborn genetic diseases; not provided; Glucocorticoid resistance
- F65L (p.Phe65Leu), 1000Genomes rs6192, ESP rs6192, ExAC rs6192, TOPMed rs6192, REVEL 0.09, CADD 22.50, Benign
- F65V (p.Phe65Val), rs6192, ClinGen CA3487117, ClinVar RCV000896237, ClinVar RCV001152116, REVEL 0.08, CADD 22.40, Benign/Likely benign, not provided; Glucocorticoid resistance
- K67E (p.Lys67Glu), Ensembl rs1840095464
- G68V (p.Gly68Val), cosmic curated COSV51544, gnomAD rs1421768594, REVEL 0.53, CADD 24.50
- S69* (p.Ser69Ter), ESP rs371034256, ExAC rs371034256, TOPMed rs371034256, gnomAD rs371034256, CADD 36.00
- S69L (p.Ser69Leu), ESP rs371034256, ExAC rs371034256, TOPMed rs371034256, gnomAD rs371034256, REVEL 0.07, CADD 21.70
- V70A (p.Val70Ala), cosmic curated COSV51542, REVEL 0.06, CADD 12.30
- S71R (p.Ser71Arg), gnomAD rs1477109172, REVEL 0.09, CADD 23.10
- N72D (p.Asn72Asp), UniProt VAR 075797, MetaLR 0.10, MetaSVM -1.00, Uncertain significance
- N72S (p.Asn72Ser), gnomAD rs1248335530, REVEL 0.05, CADD 19.60
- A73V (p.Ala73Val), rs376527205, cosmic curated COSV51542, ESP rs376527205, ExAC rs376527205, REVEL 0.01, CADD 0.19, Variant assessed as somatic; moderate impact.
- Q74H (p.Gln74His), ExAC rs772411187, gnomAD rs772411187, REVEL 0.08, CADD 21.70, Uncertain significance, Glucocorticoid resistance
- Q74K (p.Gln74Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Q74L (p.Gln74Leu), ExAC rs764541357, TOPMed rs764541357, gnomAD rs764541357, REVEL 0.04, CADD 22.40
- Q74R (p.Gln74Arg), ExAC rs764541357, TOPMed rs764541357, gnomAD rs764541357, REVEL 0.05, CADD 21.90
- Q75L (p.Gln75Leu), cosmic curated COSV10802, MetaLR 0.11, MetaSVM -1.06
- Q75R (p.Gln75Arg), TOPMed rs1840088122, gnomAD rs1840088122, REVEL 0.22, CADD 24.90
- P76S (p.Pro76Ser), NCI-TCGA TCGA novel, MetaLR 0.20, MetaSVM -0.69, Variant assessed as somatic; moderate impact.
- D77Y (p.Asp77Tyr), cosmic curated COSV51540
- S79F (p.Ser79Phe), NCI-TCGA Cosmic COSV9919, cosmic curated COSV99196, Ensembl rs1840086854, REVEL 0.39, CADD 30.00, Uncertain significance, Glucocorticoid resistance
- S79T (p.Ser79Thr), ExAC rs759250154, gnomAD rs759250154
- A81V (p.Ala81Val), cosmic curated COSV51543, REVEL 0.26, CADD 28.90
- V82D (p.Val82Asp), rs1216951244, cosmic curated COSV10634, gnomAD rs1216951244, REVEL 0.59, CADD 29.90, Variant assessed as somatic; moderate impact.
- S83L (p.Ser83Leu), NCI-TCGA Cosmic COSV5154, cosmic curated COSV51546, MetaLR 0.24, MetaSVM -0.65, Variant assessed as somatic; moderate impact.
- L84F (p.Leu84Phe), ExAC rs770476389, TOPMed rs770476389, gnomAD rs770476389, REVEL 0.31, CADD 24.90, Uncertain significance, Inborn genetic diseases
- L84R (p.Leu84Arg), NCI-TCGA Cosmic COSV5154, cosmic curated COSV51545, Variant assessed as somatic; moderate impact.
- L84V (p.Leu84Val), rs770476389, ClinGen CA3487107, ClinVar RCV003320451, ExAC rs770476389, REVEL 0.27, CADD 24.20, Uncertain significance, not specified
- M86V (p.Met86Val), rs772735144, ClinGen CA3487105, ClinVar RCV003553776, ExAC rs772735144, REVEL 0.25, CADD 25.70, Uncertain significance, not provided
- G87R (p.Gly87Arg), Ensembl rs959170340
- L88Q (p.Leu88Gln), rs2480138329, ClinGen CA361866955, ClinVar RCV003667965, REVEL 0.43, CADD 28.00, Uncertain significance, not provided
- Y89C (p.Tyr89Cys), rs200468789, ClinGen CA3487103, ClinVar RCV003731335, ClinVar RCV004756542, REVEL 0.34, CADD 29.40, Conflicting interpretations, Glucocorticoid resistance; Inborn genetic diseases; not provided
- M90T (p.Met90Thr), Ensembl rs1840080907, REVEL 0.41, CADD 24.40
- M90V (p.Met90Val), ExAC rs781203346, TOPMed rs781203346, gnomAD rs781203346, REVEL 0.32, CADD 25.70
- G91E (p.Gly91Glu), cosmic curated COSV51546, REVEL 0.29, CADD 24.00
- G91R (p.Gly91Arg), TOPMed rs1840080421, REVEL 0.34, CADD 27.80
- E94N (p.Glu94Asn), NCI-TCGA TCGA novel, MetaLR 0.14, MetaSVM -0.92, Variant assessed as somatic; high impact.
- K96R (p.Lys96Arg), cosmic curated COSV10457, MetaLR 0.32, MetaSVM -0.37
- V97M (p.Val97Met), rs886060062, ClinGen CA10623094, ClinVar RCV000260278, Ensembl rs886060062, AlphaMissense 0.15, MetaLR 0.20, Uncertain significance, Glucocorticoid resistance
- M98T (p.Met98Thr), gnomAD rs1333779302, REVEL 0.33, CADD 26.20
- M98V (p.Met98Val), ESP rs145020010, TOPMed rs145020010, gnomAD rs145020010, REVEL 0.27, CADD 23.90, Uncertain significance, Glucocorticoid resistance
- G99R (p.Gly99Arg), rs72542740, NCI-TCGA Cosmic COSV9919, cosmic curated COSV99196, Ensembl rs72542740, AlphaMissense 0.44, MetaLR 0.28, Variant assessed as somatic; moderate impact.
- N100S (p.Asn100Ser), rs1412792500, ClinGen CA361866875, ClinVar RCV002868227, TOPMed rs1412792500, REVEL 0.04, CADD 18.30, Uncertain significance, Inborn genetic diseases
- D101A (p.Asp101Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- D101E (p.Asp101Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- D101H (p.Asp101His), NCI-TCGA Cosmic COSV5154, cosmic curated COSV51546, NCI-TCGA Cosmic COSV9919, REVEL 0.26, CADD 26.40, Variant assessed as somatic; moderate impact.
- D101N (p.Asp101Asn), NCI-TCGA Cosmic COSV5154, NCI-TCGA Cosmic COSV9919, cosmic curated COSV99196, MetaLR 0.11, MetaSVM -1.01, Variant assessed as somatic; moderate impact.
- L102P (p.Leu102Pro), NCI-TCGA Cosmic COSV9919, cosmic curated COSV99196, Variant assessed as somatic; moderate impact.
- G103R (p.Gly103Arg), rs2151941570, ClinGen CA361866858, ClinVar RCV002000775, Ensembl rs2151941570, AlphaMissense 0.19, MetaLR 0.10, Uncertain significance, not provided
- P105R (p.Pro105Arg), TOPMed rs1353083246, gnomAD rs1353083246, REVEL 0.21, CADD 27.30
- Q106* (p.Gln106Ter), NCI-TCGA Cosmic COSV5154, cosmic curated COSV51544, Variant assessed as somatic; high impact.
- G108A (p.Gly108Ala), rs1840071728, ClinGen CA361866818, ClinVar RCV004491289, gnomAD rs1840071728, REVEL 0.10, CADD 23.60, Uncertain significance, Inborn genetic diseases
- Q109E (p.Gln109Glu), TOPMed rs1486098461, gnomAD rs1486098461, REVEL 0.26, CADD 25.90
- I110L (p.Ile110Leu), gnomAD rs1294585802, REVEL 0.05, CADD 20.00
- I110T (p.Ile110Thr), gnomAD rs1840070278, REVEL 0.03, CADD 17.90
- I110V (p.Ile110Val), gnomAD rs1294585802, REVEL 0.05, CADD 19.10
- S111G (p.Ser111Gly), TOPMed rs941700497, gnomAD rs941700497, REVEL 0.03, CADD 19.40
- L112F (p.Leu112Phe), rs542110718, UniProt VAR 015629, 1000Genomes rs542110718, TOPMed rs542110718, REVEL 0.05, CADD 23.30
- L112R (p.Leu112Arg), gnomAD rs901577676, REVEL 0.21, CADD 27.00, Uncertain significance, Glucocorticoid resistance
- S113F (p.Ser113Phe), rs764178904, NCI-TCGA Cosmic COSV5154, cosmic curated COSV51547, ExAC rs764178904, REVEL 0.27, CADD 24.30, Uncertain significance, Glucocorticoid resistance
- S114L (p.Ser114Leu), rs756635644, NCI-TCGA Cosmic COSV9919, cosmic curated COSV99196, ExAC rs756635644, AlphaMissense 0.07, MetaLR 0.15, Variant assessed as somatic; moderate impact.
- G115R (p.Gly115Arg), cosmic curated COSV10634
- E116* (p.Glu116Ter), cosmic curated COSV10457
- E116K (p.Glu116Lys), ExAC rs202019957, TOPMed rs202019957, gnomAD rs202019957, REVEL 0.24, CADD 27.40
- T117A (p.Thr117Ala), ExAC rs762597404, TOPMed rs762597404, gnomAD rs762597404, REVEL 0.27, CADD 26.90
- T117I (p.Thr117Ile), Ensembl rs991271047, MetaLR 0.26, MetaSVM -0.72
- D118N (p.Asp118Asn), TOPMed rs1223326476, REVEL 0.05, CADD 20.90, Uncertain significance, Glucocorticoid resistance
- D118Y (p.Asp118Tyr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L119F (p.Leu119Phe), gnomAD rs1840063196, REVEL 0.06, CADD 9.52
- L119V (p.Leu119Val), cosmic curated COSV51544
- K120N (p.Lys120Asn), NCI-TCGA TCGA novel, MetaLR 0.03, MetaSVM -1.07, Variant assessed as somatic; moderate impact.
- K120Q (p.Lys120Gln), ExAC rs567678166, gnomAD rs567678166, REVEL 0.03, CADD 19.40
- K120R (p.Lys120Arg), gnomAD rs1840061926, REVEL 0.03, CADD 10.50
- L121P (p.Leu121Pro), gnomAD rs1337459650, REVEL 0.42, CADD 28.60
- L122S (p.Leu122Ser), Ensembl rs1840060646
- E123D (p.Glu123Asp), gnomAD rs1397993996, REVEL 0.24, CADD 23.80
- S125G (p.Ser125Gly), ExAC rs768442683, TOPMed rs768442683, gnomAD rs768442683, REVEL 0.34, CADD 28.60, Uncertain significance
- S125R (p.Ser125Arg), ExAC rs768442683, TOPMed rs768442683, gnomAD rs768442683, REVEL 0.39, CADD 24.00, Uncertain significance, Glucocorticoid resistance
- I126F (p.Ile126Phe), ExAC rs776690628, TOPMed rs776690628, gnomAD rs776690628, REVEL 0.34, CADD 28.20
- I126V (p.Ile126Val), ExAC rs776690628, TOPMed rs776690628, gnomAD rs776690628, REVEL 0.22, CADD 26.00, Uncertain significance, not provided
- A127E (p.Ala127Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A127V (p.Ala127Val), gnomAD rs1179697284, REVEL 0.31, CADD 27.20
- N128D (p.Asn128Asp), TOPMed rs1473567916, gnomAD rs1473567916, REVEL 0.13, CADD 21.90
- N128S (p.Asn128Ser), NCI-TCGA TCGA novel, MetaLR 0.03, MetaSVM -1.08, Variant assessed as somatic; moderate impact.
- N130H (p.Asn130His), gnomAD rs1197425994, REVEL 0.18, CADD 25.60
- N130I (p.Asn130Ile), ESP rs72481830, ExAC rs72481830, TOPMed rs72481830, gnomAD rs72481830, REVEL 0.16, CADD 16.90
- N130S (p.Asn130Ser), ESP rs72481830, ExAC rs72481830, TOPMed rs72481830, gnomAD rs72481830, REVEL 0.04, CADD 3.81
- R131M (p.Arg131Met), cosmic curated COSV99196, MetaLR 0.09, MetaSVM -1.03
Public NR3C1 analysis runs
- NR3C1 analysis run — NR3C1 (1,075 variants) — completed 2026-08-19